GlassScriptPhysician profile
Ashley T Owyang
NPI 1245513571
$50,353.83
in general payments reported to CMS, 2019-2025
35 companies · $3,005 in 2025
The $3,005 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,143 · 2020: $1,359 · 2021: $35K · 2022: $2,792 · 2023: $2,230 · 2024: $3,139 · 2025: $3,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,624 · Consulting Fee: $450 · Honoraria: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,624.33 |
| Consulting Fee | $450.00 |
| Honoraria | $299.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $31,993.49 | 2019-2025 | Rocklatan, Wavelight Refractive Suite, Clareon |
| Rxsight INC | $2,013.80 | 2021-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Abbvie INC. | $1,754.43 | 2022-2025 | |
| Glaukos Corporation | $1,635.51 | 2019-2025 | Ce-Marked Kxla System, Photrexa, Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,322.30 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $1,202.46 | 2019-2021 | |
| Oyster Point Pharma, INC. | $1,196.34 | 2022-2023 | Tyrvaya |
| Bausch & Lomb Americas INC. | $964.52 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $926.70 | 2019-2025 | Tearcare System |
| Sun Pharmaceutical Industries INC. | $863.63 | 2019-2025 | Cequa |
| Mallinckrodt Hospital Products INC. | $780.62 | 2020-2025 | Acthar |
| Biotissue Holdings INC. | $638.92 | 2019-2025 | |
| Optovue, INC. | $617.59 | 2019 | |
| Dompe US, INC. | $563.37 | 2021-2025 | Oxervate |
| Allergan, INC. | $543.10 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $532.79 | 2024-2025 | Xdemvy |
| Lensar, INC. | $516.00 | 2019 | |
| Kala Pharmaceuticals, INC. | $303.86 | 2021-2022 | |
| Alcon Research LLC | $270.67 | 2019 | |
| Amgen INC. | $251.32 | 2025 | Tepezza |
| Shire North American Group INC | $221.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $205.69 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $161.44 | 2024-2025 | Purified Cortrophin Gel |
| Nova Eye, INC. | $150.19 | 2023-2024 | |
| Eyevance Pharmaceuticals LLC | $138.41 | 2019-2023 | Flarex |
| Carl Zeiss Meditec USA, INC. | $130.84 | 2024 | Mel 90, Iolmaster 700, Quatera 700 |
| Carl Zeiss Meditec, INC. | $115.70 | 2021 | |
| Harrow Eye, LLC | $89.23 | 2024-2025 | Vevye, Iheezo |
| Thea Pharma INC. | $65.64 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $60.86 | 2019-2025 | Tecnis Simplicity, Amo Phaco Needle |
| Ivantis, INC | $48.24 | 2020 | |
| New World Medical,INC. | $20.07 | 2019 | |
| Ocular Therapeutix, INC. | $19.72 | 2019 | |
| Beaver-Visitec International, INC. | $18.45 | 2021 | |
| Staar Surgical Company | $16.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$97.04 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Owyang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.